Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697184 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
A Phase 1 study of Chronic Lymphocytic Leukemia and CLL, sponsored by BeiGene.
- Active
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 17
- Study locations
NCT06697184 is a Phase 1 study of Chronic Lymphocytic Leukemia and CLL that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 56 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (69% lower). The trial reports 17 study locations across 11 states.
The verdict
NCT06697184, a Phase 1 study of Chronic Lymphocytic Leukemia and CLL, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Sonrotoclax
Study Locations (17)
Other
- Chu Dijon - Dijon
- Chu Montpellier Hopital Saint Eloi - Montpellier
- Iuct Oncopole - Toulouse
- Queen Elizabeth Hospital - Birmingham
- St Jamess University Hospital - Leeds
Victoria
- Cabrini Hospital Malvern - Malvern East
- The Alfred Hospital - Melbourne
Western Australia
- Rockingham Hospital - Cooloongup
- Linear Clinical Research - Nedlands
Florida
- Moffitt Cancer Center - Tampa
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Kansas
- The University of Kansas Cancer Center - Westwood
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06697184
The ClinicalTrials.gov registry entry for NCT06697184 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (69% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT06697184 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Other, Victoria, Western Australia.
Frequently Asked Questions
What is clinical trial NCT06697184 about?
NCT06697184 is a clinical study titled "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.". The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
What is the current status of trial NCT06697184?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2025-01-23. Estimated completion is 2027-12-31.
What conditions does trial NCT06697184 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, CLL.
What interventions are being tested in trial NCT06697184?
The interventions under investigation include: Zanubrutinib (DRUG), Sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT06697184?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06697184 being conducted?
This trial has 17 study locations across Florida, Indiana, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.